ArriVent BioPharmaAVBP
About: ArriVent BioPharma Inc is a clinical stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize team's deep drug development experience to maximize the potential of lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.
Employees: 40
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
175% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 8
4% more capital invested
Capital invested by funds: $389M [Q1] → $404M (+$14.9M) [Q2]
0% more funds holding
Funds holding: 53 [Q1] → 53 (+0) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 4 [Q1] → 4 (+0) [Q2]
0% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 11
3.79% less ownership
Funds ownership: 68.44% [Q1] → 64.65% (-3.79%) [Q2]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
6 analyst ratings
Citigroup Yigal Nochomovitz 57% 1-year accuracy 21 / 37 met price target | 25%upside $36 | Buy Maintained | 11 Sept 2024 |
Oppenheimer Jeff Jones 45% 1-year accuracy 9 / 20 met price target | 35%upside $39 | Outperform Reiterated | 10 Sept 2024 |
Goldman Sachs Corinne Johnson 100% 1-year accuracy 2 / 2 met price target | 32%upside $38 | Buy Maintained | 10 Sept 2024 |
HC Wainwright & Co. Robert Burns 46% 1-year accuracy 66 / 145 met price target | 25%upside $36 | Buy Maintained | 10 Sept 2024 |
HC Wainwright & Co. Robert Burns 46% 1-year accuracy 66 / 145 met price target | 4%upside $30 | Buy Maintained | 16 Aug 2024 |
